Towards evidence based medicine for paediatricians: What are the options for treating latent TB infection in children?

Archives of Disease in Childhood

Volumn 98, Issue 6, 2013, Pages 468-473

  Gwee, Amanda ^a   Coghlan, Benjamin ^b,c   Curtis, Nigel ^a,d,e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b BURNET INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

BCG VACCINATION; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HEADACHE; HEPATITIS; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MONOTHERAPY; NAUSEA; NOTE; PATIENT COMPLIANCE; PEDIATRICIAN; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN ALLERGY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; CHILD; DOSE RESPONSE; GENERAL PAEDIATRICS; INFECTIOUS DISEASES; PRESCHOOL CHILD; RESPIRATORY; REVIEW;

GENERAL PAEDIATRICS; INFECTIOUS DISEASES; RESPIRATORY;

ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISONIAZID; LATENT TUBERCULOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN;

EID: 84877349946     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303876     Document Type: Note

References (20)

1. Rutherford ME, Hill PC, Triasih R, et al. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health 2012;17;1264-73.
2. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004;8:392-402. (Pubitemid 38624845)
3. Division of Tuberculosis Elimination. Latent tuberculosis infection: a guide for primary health care providers. Atlanta: Centers for Disease Control and Prevention, 2012. http://www.cdc.gov/tb/publications/LTBI/diagnosis.htm#1 (accessed 1 Feb 2013).
4. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control (accessed 1 Feb 2013). Royal College of Physicians: London, 2011.
5. Department of Health, Victoria, Australia. Tuberculosis Management, prevention and control of tuberculosis: Guidelines for health care providers 2002-2005. http://ideas.health.vic.gov.au/diseases/tuberculosis-management- guide.asp (accessed 1 Feb 2013).
6. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47.
7. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;2:CD001363.
8. van Zyl S, Marais BJ, Hesseling AC, et al. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006;10:13-18. (Pubitemid 43266271)
9. Rennie TW, Bothamley GH, Engova D, et al. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007;30:728-35. (Pubitemid 351194834)
10. McNab BD, Marciniuk DD, Alvi RA, et al. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains aborigines. Am J Respir Crit Care Med 2000;162:989-93.
11. Cook PP, Maldonado RA, Yarnell CT, et al. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clin Infect Dis 2006;43:271-5. (Pubitemid 44078895)
12. Sterling TR, Villarino ME, Borisov AS, et al. Threemonths of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.
13. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. (Pubitemid 47378885)
14. Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis 2005;9:276-81. (Pubitemid 40392942)
15. Page KR, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-70.
16. Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130:1712-7.
17. Li J, Munsiff SS, Tarantino T, et al. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis 2010;14:e292-7.
18. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99:465-71.
19. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71.
20. Bright-Thomas R, Nandwani S, Smith J, et al. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child 2010;95:600-2.